5 research outputs found
Quantification of Human Kallikrein‑2 in Clinical Samples by Selected Reaction Monitoring
Recently, the number of mass spectrometry-based
quantification
assays has been increased, partially due to the global efforts of
chromosome-centric human proteome project (C-HPP). Our goal at the
Chromosome 19 Consortium is to provide novel selected reaction monitoring
(SRM) assays of proteins coded on chromosome 19. We have selected
the two most useful signature peptides (NSQVWLGR and HNLFEPEDTGQR)
of human kallikrein-2 (hK2 – NX_P20151) and developed an SRM
assay. Details of the analytical parameters, including multiple transitions
by peptides, are presented. The endogenous levels of hK2 were determined
in clinical samples (<i>n</i> = 35). The limit of quantification
was also estimated by spiking heavy isotope-labeled peptides into
seminal plasma samples at various concentrations (LOQ ≈ 29
ng/mL)
Chromosome 19 Annotations with Disease Speciation: A First Report from the Global Research Consortium
A first research development progress report of the Chromosome
19 Consortium with members from Sweden, Norway, Spain, United States,
China and India, a part of the Chromosome-centric Human Proteome Project
(C-HPP) global initiative, is presented (http://www.c-hpp.org). From the chromosome 19 peptide-targeted library constituting 6159
peptides, a pilot study was conducted using a subset with 125 isotope-labeled
peptides. We applied an annotation strategy with triple quadrupole,
ESI-Qtrap, and MALDI mass spectrometry platforms, comparing the quality
of data within and in between these instrumental set-ups. LC–MS
conditions were outlined by multiplex assay developments, followed
by MRM assay developments. SRM was applied to biobank samples, quantifying
kallikrein 3 (prostate specific antigen) in plasma from prostate cancer
patients. The antibody production has been initiated for more than
1200 genes from the entire chromosome 19, and the progress developments
are presented. We developed a dedicated transcript microarray to serve
as the mRNA identifier by screening cancer cell lines. NAPPA protein
arrays were built to align with the transcript data with the Chromosome
19 NAPPA chip, dedicated to 90 proteins, as the first development
delivery. We have introduced an IT-infrastructure utilizing a LIMS
system that serves as the key interface for the research teams to
share and explore data generated within the project. The cross-site
data repository will form the basis for sample processing, including
biological samples as well as patient samples from national Biobanks
Chromosome 19 Annotations with Disease Speciation: A First Report from the Global Research Consortium
A first research development progress report of the Chromosome
19 Consortium with members from Sweden, Norway, Spain, United States,
China and India, a part of the Chromosome-centric Human Proteome Project
(C-HPP) global initiative, is presented (http://www.c-hpp.org). From the chromosome 19 peptide-targeted library constituting 6159
peptides, a pilot study was conducted using a subset with 125 isotope-labeled
peptides. We applied an annotation strategy with triple quadrupole,
ESI-Qtrap, and MALDI mass spectrometry platforms, comparing the quality
of data within and in between these instrumental set-ups. LC–MS
conditions were outlined by multiplex assay developments, followed
by MRM assay developments. SRM was applied to biobank samples, quantifying
kallikrein 3 (prostate specific antigen) in plasma from prostate cancer
patients. The antibody production has been initiated for more than
1200 genes from the entire chromosome 19, and the progress developments
are presented. We developed a dedicated transcript microarray to serve
as the mRNA identifier by screening cancer cell lines. NAPPA protein
arrays were built to align with the transcript data with the Chromosome
19 NAPPA chip, dedicated to 90 proteins, as the first development
delivery. We have introduced an IT-infrastructure utilizing a LIMS
system that serves as the key interface for the research teams to
share and explore data generated within the project. The cross-site
data repository will form the basis for sample processing, including
biological samples as well as patient samples from national Biobanks
Chromosome 19 Annotations with Disease Speciation: A First Report from the Global Research Consortium
A first research development progress report of the Chromosome
19 Consortium with members from Sweden, Norway, Spain, United States,
China and India, a part of the Chromosome-centric Human Proteome Project
(C-HPP) global initiative, is presented (http://www.c-hpp.org). From the chromosome 19 peptide-targeted library constituting 6159
peptides, a pilot study was conducted using a subset with 125 isotope-labeled
peptides. We applied an annotation strategy with triple quadrupole,
ESI-Qtrap, and MALDI mass spectrometry platforms, comparing the quality
of data within and in between these instrumental set-ups. LC–MS
conditions were outlined by multiplex assay developments, followed
by MRM assay developments. SRM was applied to biobank samples, quantifying
kallikrein 3 (prostate specific antigen) in plasma from prostate cancer
patients. The antibody production has been initiated for more than
1200 genes from the entire chromosome 19, and the progress developments
are presented. We developed a dedicated transcript microarray to serve
as the mRNA identifier by screening cancer cell lines. NAPPA protein
arrays were built to align with the transcript data with the Chromosome
19 NAPPA chip, dedicated to 90 proteins, as the first development
delivery. We have introduced an IT-infrastructure utilizing a LIMS
system that serves as the key interface for the research teams to
share and explore data generated within the project. The cross-site
data repository will form the basis for sample processing, including
biological samples as well as patient samples from national Biobanks
Chromosome 19 Annotations with Disease Speciation: A First Report from the Global Research Consortium
A first research development progress report of the Chromosome
19 Consortium with members from Sweden, Norway, Spain, United States,
China and India, a part of the Chromosome-centric Human Proteome Project
(C-HPP) global initiative, is presented (http://www.c-hpp.org). From the chromosome 19 peptide-targeted library constituting 6159
peptides, a pilot study was conducted using a subset with 125 isotope-labeled
peptides. We applied an annotation strategy with triple quadrupole,
ESI-Qtrap, and MALDI mass spectrometry platforms, comparing the quality
of data within and in between these instrumental set-ups. LC–MS
conditions were outlined by multiplex assay developments, followed
by MRM assay developments. SRM was applied to biobank samples, quantifying
kallikrein 3 (prostate specific antigen) in plasma from prostate cancer
patients. The antibody production has been initiated for more than
1200 genes from the entire chromosome 19, and the progress developments
are presented. We developed a dedicated transcript microarray to serve
as the mRNA identifier by screening cancer cell lines. NAPPA protein
arrays were built to align with the transcript data with the Chromosome
19 NAPPA chip, dedicated to 90 proteins, as the first development
delivery. We have introduced an IT-infrastructure utilizing a LIMS
system that serves as the key interface for the research teams to
share and explore data generated within the project. The cross-site
data repository will form the basis for sample processing, including
biological samples as well as patient samples from national Biobanks